Adaptive Biotechnologies Touts clonoSEQ MRD Growth, Targets Companywide Profitability in 2026 [Yahoo! Finance]
Adaptive Biotechnologies Corporation (ADPT)
Last adaptive biotechnologies corporation earnings: 2/26 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
adhc.com
Company Research
Source: Yahoo! Finance
blood-based testing and deeper EMR/community penetration that management says leaves significant upside in a roughly $5.5B TAM. Adaptive says the MRD unit reached positive adjusted EBITDA in 2025 and the company expects positive adjusted EBITDA and positive free cash flow companywide in 2026 , forecasting 30% clinical volume growth in 2026, an ASP of about $1,400, and sequencing gross margins above 70%. The immune-medicine arm has expanded its mapped dataset to 5 million paired T-cell receptors and is monetizing via data deals (including Pfizer), but management is prioritizing data generation and predictive modeling over near-term IND work, guiding 2026 cash burn to roughly $15–20M. Interested in Adaptive Biotechnologies Corporation? Here are five stocks we like better. Adaptive Biotechnologies (NASDAQ:ADPT) used a presentation at the J.P. Morgan healthcare conference to outline growth drivers for its clonoSEQ minimal residual disease (MRD) franchise and to describe a capital-
Show less
Read more
Impact Snapshot
Event Time:
ADPT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ADPT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ADPT alerts
High impacting Adaptive Biotechnologies Corporation news events
Weekly update
A roundup of the hottest topics
ADPT
News
- Adaptive Biotechnologies Announces Preliminary Fourth Quarter and Full Year 2025 ResultsGlobeNewswire
- Adaptive Biotechnologies (NASDAQ:ADPT) had its "buy" rating reaffirmed by analysts at Cowen Inc.MarketBeat
- Adaptive Biotechnologies to Present at the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswire
- Adaptive Biotechnologies: 2026 Is The Durability Test, Not The Hype Cycle [Seeking Alpha]Seeking Alpha
- Adaptive Biotechnologies Announces Two Immune Receptor Licensing Agreements with Pfizer [Yahoo! Finance]Yahoo! Finance
ADPT
Earnings
- 11/5/25 - Beat
ADPT
Sec Filings
- 1/14/26 - Form 4
- 1/14/26 - Form 4
- 1/12/26 - Form 144
- ADPT's page on the SEC website